About Novavax Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.novavax.com/?locale=US
Frequently Asked Questions
What is the 52-week range for NVAX?
The 52-week high is $11.97 and the 52-week low is $6.2.
What is the P/E ratio for NVAX?
The P/E ratio data is currently unavailable.
What is the dividend yield for NVAX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 283.08%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -59.87%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 11.32.
Analyst Recommendation Trends
Wall Street analyst consensus for NVAX over the last few months:
Latest NVAX News
3 Overrated Stocks We Approach with Caution
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $10.79, denoting a +1.53% move from the preceding trading day.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
3 Volatile Stocks with Questionable Fundamentals
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
In the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.
Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears
Legislative headlines, not company announcements, have been steering attention toward Novavax (NVAX). Bipartisan lawmakers recently introduced the Protecting Approved Care Act, and the proposal has weighed on several healthcare stocks, including this vaccine developer. Recent trading reflects that pressure. Novavax’s share price is down 3.75% over the last day and 9.42% over the past week. The 30-day share price return of 14.66% feeds into a stronger year-to-date gain of 29.45% and a more...
Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?
Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...
Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.
Novavax (NVAX) Laps the Stock Market: Here's Why
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
3 Russell 2000 Stocks We’re Skeptical Of
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Novavax, Inc. (NVAX) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 10:00 AM EDTCompany ParticipantsJames Kelly - Executive VP, CFO...
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference
Novavax (NASDAQ:NVAX) outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healt
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax, Inc. (NVAX) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 9:45 AM EDTCompany ParticipantsJohn Jacobs - President,...
3 of Wall Street’s Favorite Stocks with Open Questions
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-20 | Rodgers Richard J | -18,880 | - | - |
| 2026-06-20 | Rodgers Richard J | +18,880 | - | - |
| 2026-06-20 | King Rachel K. | -18,880 | - | - |
| 2026-06-20 | King Rachel K. | +18,880 | - | - |
| 2026-06-20 | DOUGLAS RICHARD | -18,880 | - | - |
| 2026-06-20 | DOUGLAS RICHARD | +18,880 | - | - |
| 2026-06-20 | MCGLYNN MARGARET G | -18,880 | - | - |
| 2026-06-20 | MCGLYNN MARGARET G | +18,880 | - | - |
| 2026-06-20 | MOTT DAVID M | -18,880 | - | - |
| 2026-06-20 | MOTT DAVID M | +18,880 | - | - |
| 2026-06-20 | Alton Gregg H | -18,880 | - | - |
| 2026-06-20 | Alton Gregg H | +18,880 | - | - |
| 2026-06-18 | Rodgers Richard J | +14,180 | - | - |
| 2026-06-18 | Rodgers Richard J | +21,270 | - | - |
| 2026-06-18 | King Rachel K. | +14,180 | - | - |
| 2026-06-18 | King Rachel K. | +21,270 | - | - |
| 2026-06-18 | DOUGLAS RICHARD | +14,180 | - | - |
| 2026-06-18 | DOUGLAS RICHARD | +21,270 | - | - |
| 2026-06-18 | MCGLYNN MARGARET G | +14,180 | - | - |
| 2026-06-18 | MCGLYNN MARGARET G | +21,270 | - | - |
| 2026-06-18 | MOTT DAVID M | +14,180 | - | - |
| 2026-06-18 | MOTT DAVID M | +21,270 | - | - |
| 2026-06-18 | Alton Gregg H | +14,180 | - | - |
| 2026-06-18 | Alton Gregg H | +21,270 | - | - |
| 2026-06-18 | Shiver John W. | +14,180 | - | - |
| 2026-06-18 | Shiver John W. | +21,270 | - | - |
| 2026-06-18 | Newton Charles W. | +14,180 | - | - |
| 2026-06-18 | Newton Charles W. | +21,270 | - | - |
| 2026-04-25 | Newton Charles W. | -9,520 | - | - |
| 2026-04-25 | Newton Charles W. | +9,520 | - | - |
| 2026-04-14 | Walker Robert Edward | +66,000 | - | - |
| 2026-04-14 | Walker Robert Edward | +99,500 | - | - |
| 2026-03-10 | Shiver John W. | -7,947 | - | - |
| 2026-03-10 | Shiver John W. | +7,947 | - | - |
| 2026-03-07 | Kelly James Patrick | -12,223 | - | - |
| 2026-03-07 | Kelly James Patrick | -5,904 | $9.98 | $58,922 |
| 2026-03-07 | Kelly James Patrick | +12,223 | - | - |
| 2026-03-03 | Kelly James Patrick | -43,167 | - | - |
| 2026-03-03 | Kelly James Patrick | -20,850 | $9.49 | $197,867 |
| 2026-03-03 | Kelly James Patrick | +43,167 | - | - |
| 2026-03-03 | Jacobs John C | -150,167 | - | - |
| 2026-03-03 | Jacobs John C | -69,288 | $9.49 | $657,543 |
| 2026-03-03 | Jacobs John C | +150,167 | - | - |
| 2026-03-03 | O'Hara Elaine | -56,334 | - | - |
| 2026-03-03 | O'Hara Elaine | -22,429 | $9.49 | $212,851 |
| 2026-03-03 | O'Hara Elaine | +56,334 | - | - |
| 2026-03-03 | Casey Mark J | -4,000 | - | - |
| 2026-03-03 | Casey Mark J | -11,378 | $9.49 | $107,977 |
| 2026-03-03 | Casey Mark J | +37,500 | - | - |
| 2026-03-03 | Draghia-Akli Ruxandra | -26,667 | - | - |
| 2026-03-03 | Draghia-Akli Ruxandra | -11,313 | $9.49 | $107,360 |
| 2026-03-03 | Draghia-Akli Ruxandra | +26,667 | - | - |
| 2026-03-02 | Kelly James Patrick | +194,000 | - | - |
| 2026-03-02 | Draghia-Akli Ruxandra | +139,500 | - | - |
| 2026-03-02 | Casey Mark J | +152,000 | - | - |
| 2026-03-02 | Jacobs John C | +551,500 | - | - |
| 2026-03-02 | O'Hara Elaine | +177,500 | - | - |
| 2026-03-02 | Draghia-Akli Ruxandra | +139,500 | $9.09 | $1,268,055 |
| 2026-03-02 | Draghia-Akli Ruxandra | +93,000 | - | - |
| 2026-03-02 | Jacobs John C | +551,500 | $9.09 | $5,013,135 |
| 2026-03-02 | Jacobs John C | +367,500 | - | - |
| 2026-03-02 | Kelly James Patrick | +194,000 | $9.09 | $1,763,460 |
| 2026-03-02 | Kelly James Patrick | +129,500 | - | - |
| 2026-03-02 | O'Hara Elaine | +177,500 | $9.09 | $1,613,475 |
| 2026-03-02 | O'Hara Elaine | +118,000 | - | - |
| 2026-03-02 | Casey Mark J | +152,000 | $9.09 | $1,381,680 |
| 2026-03-02 | Casey Mark J | +101,000 | - | - |
| 2026-03-01 | Jacobs John C | -83,333 | - | - |
| 2026-03-01 | Jacobs John C | -38,450 | $10.14 | $389,883 |
| 2026-03-01 | Jacobs John C | +83,333 | - | - |
| 2026-03-01 | Kelly James Patrick | -58,666 | - | - |
| 2026-03-01 | Kelly James Patrick | -28,366 | $10.14 | $287,631 |
| 2026-03-01 | Kelly James Patrick | +58,666 | - | - |
| 2026-03-01 | O'Hara Elaine | -40,000 | - | - |
| 2026-03-01 | O'Hara Elaine | -19,600 | - | - |
| 2026-03-01 | O'Hara Elaine | -10,969 | $10.14 | $111,226 |
| 2026-03-01 | O'Hara Elaine | +40,000 | - | - |
| 2026-03-01 | O'Hara Elaine | -5,375 | $10.14 | $54,503 |
| 2026-03-01 | O'Hara Elaine | +19,600 | - | - |
| 2026-03-01 | Casey Mark J | -4,000 | - | - |
| 2026-03-01 | Casey Mark J | -1,214 | $10.14 | $12,310 |
| 2026-03-01 | Casey Mark J | +4,000 | - | - |
| 2026-01-23 | Jacobs John C | -83,197 | - | - |
| 2026-01-23 | Jacobs John C | -39,132 | $9.17 | $358,840 |
| 2026-01-23 | Jacobs John C | +83,197 | - | - |
| 2025-12-11 | Casey Mark J | -41,899 | - | - |
| 2025-12-11 | Casey Mark J | -12,713 | $6.69 | $85,050 |
| 2025-12-11 | Casey Mark J | +41,899 | - | - |
| 2025-11-11 | Draghia-Akli Ruxandra | -14,257 | - | - |
| 2025-11-11 | Draghia-Akli Ruxandra | -6,048 | $7.4 | $44,755 |
| 2025-11-11 | Draghia-Akli Ruxandra | +14,257 | - | - |
| 2025-10-29 | Rodgers Richard J | -3,800 | - | - |
| 2025-10-29 | Rodgers Richard J | +3,800 | - | - |